A Phase 1, Multicenter, Open Label Study of YM155 Plus Docetaxel and Prednisone in Men with Advanced Hormone Refractory Prostate Cancer (HRPC)
|Effective start/end date||3/12/07 → 5/19/09|
- Astellas Pharma US, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.